Sign in
Active, not recruitingNo phase

Xeltis Peripheral Artery Disease (XPAD) Bypass Conduit Early Feasibility Study

Key facts

Who runs it
Xeltis
Where
Costa Rica1 site in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
People taking part
6 people, planned
Started
2 May 2025
Expected to end
Dec 2028
Type of study
Interventional
Treatments tested
  • Xeltis Peripheral Artery Disease (XPAD) Bypass Conduit
Record updated
6 October 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 27 criteriaShow less

Who can take part

  • Subjects with femoral artery occlusion who require elective above-knee femoral popliteal bypass surgery
  • Patient has Rutherford grade 3, 4, or 5 occlusive vascular disease and TASC C or D lesions. Rutherford grade 5 may be included with a wound, ischemia and foot infection (WiFi) classification of up to grade 2, provided there are two outflow vessels with at least one reaching the pedal arch
  • At least 18 years of age at screening
  • Suitable anatomy (assessed by a pre-procedural contrasted CT scan or previous angiogram assessed up to 90 days prior to baseline)
  • Patient has been informed of the nature of the study, agrees to its provisions, and has provided written informed consent
  • Patient has been informed and agrees to pre- and post-procedure follow-up, including follow-up angiography
  • Life expectancy of at least 24 months

Who cannot take part

  • Stroke or myocardial infarction event within 6 weeks of the procedure or evidence of prior massive stroke (Modified Rankin Scale 3 or above)
  • Previous renal transplant
  • Previous enrolment in this study
  • Unsuitable anatomy to implant the XPAD conduit (e.g. target vessel diameter smaller than anticipated; severe calcification)
  • Subject requires, or is scheduled for, a cardiac surgical procedure or a different vascular surgical procedure within 30 days of study procedure
  • Presence or history of bypass in the diseased limb
  • History of acute arterial occlusion requiring an emergent intervention
  • Uncontrolled arterial hypertension (BP >200 mmHg) at 2 successive readings
  • Uncontrolled or poorly controlled diabetes
  • Any active local or systemic infection
  • Known active bleeding disorder and/or any coagulopathy or thromboembolic disease
  • Allergies to study device (nitinol) or agents/medication, such as contrast agents or aspirin, that can't be controlled medically
  • Any other condition which, in the judgement of the investigator would preclude adequate evaluation for the safety and performance of the study conduit; Intra-operative exclusion criteria:
  • Severe chronic renal insufficiency (serum creatinine >2.5 mg/dL) or undergoing hemodialysis
  • Reduced liver function, defined as: >2x the upper limit of normal for serum bilirubin, International Normalized Ratio (INR) >1.5 or prothrombin time (PT) >18 seconds
  • Subject requires sequential extremity revascularizations or other procedures that require use of additional vascular grafts
  • Abnormal blood values that could influence patient recovery and or/ graft hemostasis
  • Known heparin-induced thrombocytopenia
  • Subject is participating in another study
  • Pregnant or breastfeeding woman or woman in fertile period not taking adequate contraceptives

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

A prospective, single arm, non-randomized early feasibility study to evaluate the preliminary safety and performance of the XPAD conduit in patients with peripheral arterial occlusive disease (PAOD), scheduled to undergo elective above-knee femoral popliteal bypass surgery.

The group in the trial

  • XPAD Bypass ConduitTreatment being tested

    Treatment: Xeltis Peripheral Artery Disease (XPAD) Bypass Conduit

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Prospective, Non-randomized, Early Feasibility Clinical Study to Assess the Feasibility of the Novel Xeltis Peripheral Artery Disease (XPAD) Bypass Conduit
Record updated
6 October 2026